tiprankstipranks
GSK reports FDA approves Arexvy RSV vaccine for older adults
The Fly

GSK reports FDA approves Arexvy RSV vaccine for older adults

GSK plc announced that the U.S. Food and Drug Administration has approved Arexvy for the prevention of lower respiratory tract disease caused by respiratory syncytial virus, or RSV, in individuals 60 years of age and older. "This is the first RSV vaccine for older adults to be approved anywhere in the world," GSK stated. Tony Wood, Chief Scientific Officer, GSK, said: "Today marks a turning point in our effort to reduce the significant burden of RSV. Arexvy is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on GSK:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles